Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4Q50

The Estrogen Receptor Alpha Ligand Binding Domain D538G Mutant in Complex with 4-hydroxytamoxifen

4Q50 の概要
エントリーDOI10.2210/pdb4q50/pdb
関連するPDBエントリー4Q13
分子名称Estrogen receptor, 4-HYDROXYTAMOXIFEN, SULFATE ION, ... (4 entities in total)
機能のキーワードacquired serm-resistance, breast cancer, activating mutation, serm-er structure, alpha helix, nuclear hormone receptor, hormone binding protein
由来する生物種Homo sapiens (human)
細胞内の位置Isoform 1: Nucleus . Isoform 3: Nucleus. Nucleus: P03372
タンパク質・核酸の鎖数8
化学式量合計240155.33
構造登録者
Fanning, S.W.,Greene, G.L. (登録日: 2014-04-15, 公開日: 2015-04-15, 最終更新日: 2024-02-28)
主引用文献Fanning, S.W.,Mayne, C.G.,Dharmarajan, V.,Carlson, K.E.,Martin, T.A.,Novick, S.J.,Toy, W.,Green, B.,Panchamukhi, S.,Katzenellenbogen, B.S.,Tajkhorshid, E.,Griffin, P.R.,Shen, Y.,Chandarlapaty, S.,Katzenellenbogen, J.A.,Greene, G.L.
Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation.
Elife, 5:-, 2016
Cited by
PubMed Abstract: Somatic mutations in the estrogen receptor alpha (ERα) gene (ESR1), especially Y537S and D538G, have been linked to acquired resistance to endocrine therapies. Cell-based studies demonstrated that these mutants confer ERα constitutive activity and antiestrogen resistance and suggest that ligand-binding domain dysfunction leads to endocrine therapy resistance. Here, we integrate biophysical and structural biology data to reveal how these mutations lead to a constitutively active and antiestrogen-resistant ERα. We show that these mutant ERs recruit coactivator in the absence of hormone while their affinities for estrogen agonist (estradiol) and antagonist (4-hydroxytamoxifen) are reduced. Further, they confer antiestrogen resistance by altering the conformational dynamics of the loop connecting Helix 11 and Helix 12 in the ligand-binding domain of ERα, which leads to a stabilized agonist state and an altered antagonist state that resists inhibition.
PubMed: 26836308
DOI: 10.7554/eLife.12792
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (3.07 Å)
構造検証レポート
Validation report summary of 4q50
検証レポート(詳細版)ダウンロードをダウンロード

252456

件を2026-04-22に公開中

PDB statisticsPDBj update infoContact PDBjnumon